SI1523496T1 - Rekombinantno proizvajanje zmesi protiteles - Google Patents

Rekombinantno proizvajanje zmesi protiteles

Info

Publication number
SI1523496T1
SI1523496T1 SI200332045T SI200332045T SI1523496T1 SI 1523496 T1 SI1523496 T1 SI 1523496T1 SI 200332045 T SI200332045 T SI 200332045T SI 200332045 T SI200332045 T SI 200332045T SI 1523496 T1 SI1523496 T1 SI 1523496T1
Authority
SI
Slovenia
Prior art keywords
mixtures
antibodies
nucleic acid
light chain
host cell
Prior art date
Application number
SI200332045T
Other languages
English (en)
Inventor
Berkel Patrick Hendrikus Cornelis Van
Ronald Hendrik Peter Brus
Abraham Bout
Ton Logtenberg
Original Assignee
Merus B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43768900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1523496(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus B V filed Critical Merus B V
Publication of SI1523496T1 publication Critical patent/SI1523496T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
SI200332045T 2002-07-18 2003-07-15 Rekombinantno proizvajanje zmesi protiteles SI1523496T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39706602P 2002-07-18 2002-07-18
EP02077953 2002-07-18
EPPCT/EP03/50201 2003-05-27
EP03764997A EP1523496B1 (en) 2002-07-18 2003-07-15 Recombinant production of mixtures of antibodies
PCT/EP2003/007690 WO2004009618A2 (en) 2002-07-18 2003-07-15 Recombinant production of mixtures of antibodies

Publications (1)

Publication Number Publication Date
SI1523496T1 true SI1523496T1 (sl) 2011-11-30

Family

ID=43768900

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332045T SI1523496T1 (sl) 2002-07-18 2003-07-15 Rekombinantno proizvajanje zmesi protiteles

Country Status (15)

Country Link
US (9) US7262028B2 (sl)
EP (2) EP1523496B1 (sl)
JP (4) JP4836451B2 (sl)
CN (3) CN105884893A (sl)
AT (1) ATE514717T1 (sl)
AU (2) AU2003250074B2 (sl)
CA (3) CA2492377C (sl)
CY (1) CY1111886T1 (sl)
DK (2) DK1523496T3 (sl)
ES (2) ES2368733T3 (sl)
HK (1) HK1070902A1 (sl)
NZ (1) NZ537277A (sl)
PT (2) PT1523496E (sl)
SI (1) SI1523496T1 (sl)
WO (1) WO2004009618A2 (sl)

Families Citing this family (287)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CA2222140C (en) 1995-06-15 2010-11-23 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
CA2756610C (en) * 2001-10-29 2015-08-25 Crucell Holland B.V. Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20050026161A1 (en) * 2002-11-01 2005-02-03 Edward Jablonski Displacement sandwich immuno-PCR
GB0230201D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Retargeting
BRPI0406678A (pt) 2003-01-07 2005-12-20 Symphogen As Método para produzir proteìnas policlonais recombinantes
WO2004065611A1 (ja) * 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗体の軽鎖スクリーニング方法
ATE469920T1 (de) * 2003-05-23 2010-06-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
EP1508576A1 (en) * 2003-08-20 2005-02-23 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
JP5912211B2 (ja) 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
AU2011218688B2 (en) * 2004-05-27 2013-01-10 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
CN102212132A (zh) 2004-05-27 2011-10-12 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
KR20070038556A (ko) 2004-07-20 2007-04-10 심포젠 에이/에스 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
PL2053408T3 (pl) 2004-07-20 2012-08-31 Symphogen As Sposób strukturalnego charakteryzowania rekombinowanego poliklonalnego białka lub poliklonalnej linii komórkowej
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
CN101065497B (zh) * 2004-11-03 2012-11-21 卢卡迪亚技术股份有限公司 用于亲和分离的微泡
DK1842226T3 (da) * 2004-11-03 2010-10-18 Iris Molecular Diagnostics Inc Homogen analytpåvisning
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
DK2824183T3 (da) * 2005-04-08 2020-09-28 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af bispecifikke antistoffer
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
AU2012201010B2 (en) * 2005-10-21 2015-01-22 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20080118501A1 (en) * 2005-10-21 2008-05-22 Gtc Biotherapeutics, Inc. Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
DE102005054628A1 (de) * 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
JP2009518320A (ja) 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
DK2006680T3 (da) * 2006-02-17 2014-06-23 Atsuo Sekiyama Indikator og fremgangsmåde til måling af biologisk belastning
KR20140057635A (ko) 2006-03-15 2014-05-13 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
ES2378407T3 (es) 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
SI2061810T1 (sl) 2006-09-05 2015-04-30 Alexion Pharmaceuticals, Inc. Postopki in sestavki za zdravljenje s protitelesi povezanih nevropatij
KR101522036B1 (ko) 2006-12-05 2015-05-20 크루셀 홀란드 비.브이. 액체 항-광견병 항체 조성물
CA2676049C (en) 2007-03-01 2018-04-10 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090068684A1 (en) 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
NL1033696C2 (nl) * 2007-04-16 2008-10-20 Friesland Brands Bv Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan.
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2152872B1 (en) * 2007-05-25 2010-09-15 Symphogen A/S Method for manufacturing a recombinant polyclonal protein
US8846867B2 (en) 2007-06-26 2014-09-30 The Trustees Of The University Of Pennsylvania Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
ES2576650T3 (es) 2007-10-18 2016-07-08 Cell Signaling Technology, Inc. Translocación y ROS quinasa mutante en el carcinoma pulmonar no microcítico humano
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009105264A1 (en) * 2008-02-21 2009-08-27 Iris International Inc. Method for early determination of recurrence after therapy for prostate cancer
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
CN102007146A (zh) * 2008-04-23 2011-04-06 西福根有限公司 用于制备多克隆蛋白质的方法
MX2010011955A (es) 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
US9035027B2 (en) 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3456193A1 (en) * 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
BRPI0918768B1 (pt) 2008-08-29 2022-08-30 Symphogen A/S Composições de anticorpo recombinante de antireceptor do fator de crescimento epidérmico
EP2159291A1 (en) 2008-09-01 2010-03-03 Agendia B.V. Means and method for determining tumor cell percentage in a sample
WO2010084197A1 (en) * 2009-01-26 2010-07-29 Genmab A/S Methods for producing mixtures of antibodies
ES2533952T3 (es) 2009-02-09 2015-04-16 Morphosys Ag Producción de mezclas oligoclonales de inmunoglobulinas en células individuales
PL2881402T3 (pl) 2009-02-12 2017-10-31 Cell Signaling Technology Inc Ekspresja zmutowanej ROS w ludzkim raku wątroby
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
CN102459346B (zh) * 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
LT3241435T (lt) 2009-07-08 2021-10-25 Kymab Limited Gyvūnų modeliai ir terapinės molekulės
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PE20130580A1 (es) 2010-03-02 2013-06-02 Abbvie Inc Proteinas terapeuticas de union a dll4
MX346731B (es) * 2010-04-23 2017-03-30 Genentech Inc * Producción de proteínas heteromultiméricas.
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
PT2606064E (pt) 2010-08-16 2015-06-08 Novimmune Sa Processos para a geração de anticorpos poliespecíficos e polivalentes
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
NZ608814A (en) 2010-09-03 2015-06-26 Stem Centrx Inc Novel modulators and methods of use
TW201631153A (zh) 2010-11-17 2016-09-01 中外製藥股份有限公司 具有替代血液凝固第ｖｉｉｉ因子之功能的多重專一性抗原結合分子
RU2627171C2 (ru) 2010-12-21 2017-08-03 Эббви Инк. Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
KR20140037036A (ko) 2011-01-03 2014-03-26 에이브이엠 바이오테크놀로지, 엘엘씨 생물제제의 맞춤형 제조 및 체세포의 재프로그래밍 방법
MX343009B (es) 2011-02-25 2016-10-21 Regeneron Pharma Ratones de una desintegrina y metaloproteasa 6 (adam6).
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA2844070A1 (en) * 2011-08-05 2013-02-14 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
CN106995822B (zh) 2011-09-19 2021-06-29 科马布有限公司 定制供人类使用的抗体、可变结构域和链
HUE061002T2 (hu) 2011-09-23 2023-04-28 Mereo Biopharma 5 Inc VEGF/DLL4-kötõ ágensek és alkalmazásaik
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013055958A1 (en) 2011-10-11 2013-04-18 Genentech, Inc. Improved assembly of bispecific antibodies
IL292030B2 (en) 2011-10-17 2023-07-01 Regeneron Pharma Mice with restricted immunoglobulin heavy chain
US8999331B2 (en) 2011-10-24 2015-04-07 Abbvie Inc. Immunobinders directed against sclerostin
RS20140202A1 (en) 2011-10-24 2014-10-31 Abbvie Inc. BIOSPECIFIC IMMUNOVELING PROTEINS DIRECTED AGAINST TNF AND IL-17
EP2773667A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
PT2793567T (pt) 2011-12-20 2019-05-27 Regeneron Pharma Murganhos de cadeia leve humanizada
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
TW201333033A (zh) 2011-12-30 2013-08-16 Abbvie Inc 雙可變域免疫球蛋白及其用途
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP3165086A1 (en) * 2012-03-06 2017-05-10 Regeneron Pharmaceuticals, Inc. Common light chain mouse
MX355732B (es) 2012-03-16 2018-04-27 Regeneron Pharma Anticuerpos con cadena ligera modificada con histidina por ingenieria genetica y animales no humanos geneticamente modificados para generarlos.
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CA2865645A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Non-human animals expressing immunoglobulin sequences ph-sensitive for antigen building
EP2825035A1 (en) 2012-03-16 2015-01-21 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
ES2655842T3 (es) 2012-04-18 2018-02-21 Cell Signaling Technology, Inc. EGFR y ROS1 en el cáncer
EA202090591A3 (ru) * 2012-04-20 2020-12-30 Мерюс Н.В. СПОСОБЫ И СРЕДСТВА ДЛЯ ПОЛУЧЕНИЯ Ig-ПОДОБНЫХ МОЛЕКУЛ
MX2019001355A (es) * 2012-05-10 2023-01-17 Bioatla Llc Anticuerpos monoclonales multiespecíficos.
ES2759617T3 (es) 2012-06-12 2020-05-11 Regeneron Pharma Animales no humanos humanizados con loci restringidos de cadena pesada de inmunoglobulina
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
ES2456823B1 (es) * 2012-09-21 2015-01-27 Consejo Superior De Investigaciones Científicas (Csic) Método de producción de repertorios complejos de moléculas recombinantes
PL2900694T3 (pl) * 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
EP2915819B1 (en) * 2012-11-05 2019-08-14 Zenyaku Kogyo Kabushikikaisha Antibody and antibody composition production method
US20140212423A1 (en) 2012-12-04 2014-07-31 Abbvie, Inc. Blood-brain barrier penetrating dual specific binding proteins
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
EP2938634A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Dual specific binding proteins having a receptor sequence
EA201500741A1 (ru) 2013-01-10 2016-01-29 Генмаб Б.В. ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
WO2014113436A1 (en) * 2013-01-15 2014-07-24 The Regents Of The University Of California Adenoviruses and their use
SG10201900580RA (en) 2013-02-20 2019-02-27 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
AU2014244079A1 (en) * 2013-03-13 2015-09-24 Regeneron Pharmaceuticals, Inc. Common light chain mouse
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
SG11201507423YA (en) 2013-03-15 2015-10-29 Abbvie Inc DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
SG11201510739TA (en) 2013-07-05 2016-01-28 Genmab As Humanized or chimeric cd3 antibodies
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX2016004420A (es) 2013-10-06 2017-03-31 Abbvie Inc Proteinas de union especificas duales dirigidas contra los receptores de células inmunes y autoantígenos de señalización de tlr.
TW201536320A (zh) 2013-12-02 2015-10-01 Abbvie Inc 治療骨性關節炎之組合物及方法
KR102378289B1 (ko) * 2014-02-10 2022-03-23 아이쥐엠 바이오사이언스 인코포레이티드 IgA 다중-특이적 결합 분자
AU2015223566B2 (en) 2014-02-28 2020-10-08 Merus N.V. Antibodies that bind EGFR and ErbB3
JP6967853B2 (ja) 2014-02-28 2021-11-17 メルス ナムローゼ フェンノートシャップ ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体
CA2942697A1 (en) 2014-03-21 2015-09-24 Lynn Macdonald Non-human animals that make single domain binding proteins
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
DK3126384T3 (da) 2014-04-01 2021-01-18 Adimab Llc Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse
EP3126383B8 (en) 2014-04-03 2019-02-27 IGM Biosciences, Inc. Modified j-chain
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
EP3140392B1 (en) 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
PT3142750T (pt) * 2014-05-13 2020-09-22 Univ Pennsylvania Composições que compreendem aav expressando construções de anticorpos duplos e suas utilizações
HUE048667T2 (hu) 2014-07-11 2020-08-28 Genmab As AXL-hez kötõdõ ellenanyagok
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3200829B1 (en) 2014-10-01 2023-12-06 Medimmune, LLC Method of conjugating a polypeptide
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CN110658340B (zh) * 2015-01-08 2023-10-31 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
AU2016209324B2 (en) 2015-01-20 2020-02-27 Igm Biosciences, Inc. Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof
IL297997A (en) 2015-03-04 2023-01-01 Igm Biosciences Inc CD20 binding compounds and their uses
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
SI3115376T1 (sl) 2015-07-10 2018-12-31 Merus N.V. Humana protitelesa, ki vežejo CD3
AU2016292762B2 (en) 2015-07-10 2022-07-28 Genmab A/S AXL-specific antibody-drug conjugates for cancer treatment
CA2992380A1 (en) 2015-07-15 2017-01-19 Genmab A/S Humanized or chimeric cd3 antibodies
AU2016311334B2 (en) * 2015-08-27 2021-12-16 Crystal Bioscience Inc. Transgenic animal for production of antibodies having a common light chain
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
LT3365373T (lt) 2015-10-23 2021-05-25 Merus N.V. Surišančios molekulės, kurios inhibuoja vėžio augimą
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
CN108495653A (zh) 2016-01-27 2018-09-04 免疫医疗有限责任公司 用于制备具有定义的糖基化模式抗体的方法
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
KR20180138205A (ko) 2016-03-22 2018-12-28 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
JP7301540B2 (ja) 2016-05-26 2023-07-03 チールー ピュージェット サウンド バイオセラピューティクス コーポレイション 抗体の混合物
KR102632202B1 (ko) 2016-07-14 2024-02-02 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
MX2019002510A (es) 2016-09-06 2019-06-24 Chugai Pharmaceutical Co Ltd Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
AU2017332452B2 (en) 2016-09-23 2021-01-07 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2018083126A1 (en) 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof
CA3045161A1 (en) 2016-12-01 2018-06-07 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Production of ricin antibodies in plant
AU2018214208A1 (en) * 2017-02-02 2019-07-11 Merck Patent Gmbh Preferred pairing of antibody domains
WO2018146317A1 (en) 2017-02-10 2018-08-16 Genmab B.V. Polypeptide variants and uses thereof
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CN110573524B (zh) 2017-03-09 2023-07-18 健玛保 针对pd-l1的抗体
CN110650752A (zh) 2017-03-31 2020-01-03 美勒斯公司 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
CN110914301A (zh) 2017-03-31 2020-03-24 健玛保控股有限公司 双特异性抗cd37抗体，单克隆抗cd37抗体及其使用方法
JP7304815B2 (ja) 2017-03-31 2023-07-07 メルス ナムローゼ フェンノートシャップ Ｅｒｂｂ－２、ｅｒｂｂ－２／ｅｒｂｂ－３陽性腫瘍を有する個体の処置のための、ｅｒｂ－２及びｅｒｂｂ－３の細胞外部分上のエピトープに結合する抗原結合部位を含むｅｒｂｂ－２標的化剤及び二重特異性抗体
BR112019024230A2 (pt) 2017-05-17 2020-06-09 Merus N.V. combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
KR20200042467A (ko) 2017-07-06 2020-04-23 메뤼스 엔.페. 이중특이적 항pd-1 tim3 항체
EA202090005A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
US11667714B2 (en) 2017-07-06 2023-06-06 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
MA49753A (fr) 2017-08-04 2020-06-10 BioNTech SE Agents de liaison se liant à pd-l1 et cd137 et leur utilisation
US11773170B2 (en) 2017-08-09 2023-10-03 Merus N.V. Antibodies that bind EGFR and cMET
KR20200049764A (ko) 2017-09-29 2020-05-08 추가이 세이야쿠 가부시키가이샤 혈액 응고 제 viii 인자(fviii) 보인자 기능 대체 활성을 갖는 다중특이성 항원 결합 분자 및 당해 분자를 유효 성분으로서 함유하는 약학적 제제
JP7317016B2 (ja) * 2017-12-19 2023-07-28 スロゼン オペレーティング， インコーポレイテッド 抗ｌｒｐ５／６抗体及び使用方法
CN111727203A (zh) 2017-12-19 2020-09-29 瑟罗泽恩公司 Wnt替代分子和其用途
US20210107988A1 (en) 2018-01-24 2021-04-15 Genmab B.V. Polypeptide variants and uses thereof
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
EP3765493A2 (en) 2018-03-12 2021-01-20 Genmab A/S Antibodies
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019182910A1 (en) * 2018-03-19 2019-09-26 Elwha Llc Compositions and methods for modified b cells expressing reassigned biological agents
KR20200139189A (ko) 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체
KR20210008380A (ko) 2018-05-03 2021-01-21 젠맵 비. 브이 항체 변이체 조합물 및 그의 용도
MA52951A (fr) 2018-06-22 2021-04-28 Genmab Holding B V Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci
WO2019243626A1 (en) 2018-06-22 2019-12-26 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2019300223A1 (en) 2018-07-13 2021-01-07 Genmab A/S Variants of CD38 antibody and uses thereof
MA53123A (fr) 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
WO2020070313A1 (en) 2018-10-04 2020-04-09 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
CA3118789A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
JP7440516B2 (ja) 2018-12-31 2024-02-28 メルス ナムローゼ フェンノートシャップ 切断多価多量体
AR117741A1 (es) 2018-12-31 2021-08-25 Merus Nv Dominios de unión mixtos
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
GB2597851A (en) 2019-02-21 2022-02-09 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
GB2599227A (en) 2019-02-21 2022-03-30 Marengo Therapeutics Inc Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
CA3131014A1 (en) 2019-02-21 2020-08-27 Andreas Loew Anti-tcr antibody molecules and uses thereof
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
TW202102544A (zh) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
WO2020225456A1 (en) 2019-05-09 2020-11-12 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
EP3966238A2 (en) 2019-05-09 2022-03-16 Merus N.V. Variant domains for multimerizing proteins and separation thereof
US20220372148A1 (en) 2019-07-05 2022-11-24 Ono Pharmaceutical Co., Ltd. A pharmaceutical composition for treating hematological cancer
BR112022001473A2 (pt) 2019-07-30 2022-03-22 Ono Pharmaceutical Co Anticorpo biespecífico
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
EP4055046A1 (en) 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
JP7183143B2 (ja) 2019-12-23 2022-12-05 日立Astemo株式会社 エンジンの制御装置
KR20230145542A (ko) 2019-12-24 2023-10-17 메뤼스 엔.페. Tgf-베타-rii 결합 단백질
EP4084821A2 (en) 2020-01-03 2022-11-09 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
US20230272105A1 (en) 2020-01-16 2023-08-31 Genmab A/S Formulations of cd38 antibodies and uses thereof
KR20220133196A (ko) 2020-01-29 2022-10-04 메뤼스 엔.페. 면역 세포 관여 효과를 조절하기 위한 수단 및 방법
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
US20210292418A1 (en) 2020-03-18 2021-09-23 Genmab A/S Antibodies
CN115397867A (zh) * 2020-04-13 2022-11-25 艾弗依姆恩治疗公司 Epcam抗体与car-t细胞
JP2023523011A (ja) 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CA3175227A1 (en) 2020-05-21 2021-11-25 Cornelis De Kruif Methods and means for the production of ig-like molecules
EP4185388A1 (en) 2020-07-23 2023-05-31 Genmab B.V. A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
CN116194477A (zh) 2020-08-06 2023-05-30 生物技术欧洲股份公司 冠状病毒s蛋白的结合剂
AU2021331076A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
EP4204450A2 (en) 2020-08-26 2023-07-05 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
BR112023004327A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar leucemia linfocítica crônica em um sujeito humano
AU2021340232A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
IL301513A (en) 2020-10-02 2023-05-01 Genmab As Antibodies able to bind to ROR2 and bispecific antibodies that bind to ROR2 and CD3
AU2021398976A1 (en) 2020-12-16 2023-07-06 Merus N.V. Multispecific antibodies for the treatment of cancer
WO2022189667A1 (en) 2021-03-12 2022-09-15 Genmab A/S Non-activating antibody variants
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
AR125815A1 (es) 2021-05-07 2023-08-16 Genmab As Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3
IL309319A (en) 2021-06-21 2024-02-01 Genmab As Combined dosage regimen CD137 and PD-L1 binding agents
US20230109496A1 (en) 2021-09-06 2023-04-06 Genmab B.V. Antibodies capable of binding to cd27, variants thereof and uses thereof
JP2023551744A (ja) 2021-10-08 2023-12-12 ジェンマブ エー／エス Ｃｄ３０及びｃｄ３に結合する抗体
WO2023146394A1 (en) 2022-01-25 2023-08-03 Merus N.V. Combination therapy for the treatment of cancer
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023218051A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2024013724A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody-drug conjugates

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5180502A (ja) 1974-12-28 1976-07-14 Seirei Ind Tsumejikufurikaeshikiseigyakutenkonsochi
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4599311A (en) * 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU600885B2 (en) 1984-05-25 1990-08-30 Zymogenetics Inc. Stable DNA constructs
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4868103A (en) * 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
ATE81724T1 (de) * 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
ATE99958T1 (de) 1989-06-08 1994-01-15 Wistar Inst Monoklonale antikoerper zur behandlung nach einem kontakt mit tollwutvirus.
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5959177A (en) † 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
EP0737746A3 (en) † 1989-12-01 1996-10-23 Pharming B.V. Production of recombinant polypeptides by bovine species and transgenic methods
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0469897A3 (en) 1990-07-31 1992-11-19 The Wistar Institute Engineered antibodies
IE76732B1 (en) * 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US6255458B1 (en) † 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69231676T2 (de) 1991-03-29 2001-05-17 Genentech Inc Methoden zur selektion von rekombinanten wirtszellen welche hohe mengen von einem gewünschten protein exprimieren
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993002190A1 (en) 1991-07-15 1993-02-04 The Wellcome Foundation Limited Production of antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
CA2087413A1 (en) * 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) * 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
SE9201984D0 (sv) * 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
ATE348175T1 (de) * 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc Method eder intrazellularen bindung von zielgerichteten molekülen
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
ES2088838T3 (es) 1992-11-13 2004-01-01 Idec Pharmaceuticals Corporation Secuencias kozak de consenso totalmente alteradas destinadas a la expresion en los mamiferos.
WO1994023046A1 (en) 1993-04-07 1994-10-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Dna sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
WO1995007358A1 (en) 1993-07-30 1995-03-16 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
US5693506A (en) † 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DE69430014D1 (de) † 1993-12-23 2002-04-04 Infigen Inc EMBRYONALE STAMMZELLEN von Huftieren ALS KERNDONATOREN UND KERNTRANSFERTECHNIKEN ZUR HERSTELLUNG CHIMÄRER UND TRANSGENER TIERE
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
FR2717187B1 (fr) 1994-03-10 1996-05-31 Transgene Sa Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt.
US6080560A (en) † 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
JPH08116978A (ja) 1994-10-18 1996-05-14 Nisshinbo Ind Inc 抗体Ｆａｂライブラリーの作製法
EP0807173B1 (en) * 1994-12-30 2007-08-08 Planet Biotechnology, Inc. Methods for producing immunoglobulins containing protection proteins in plants and their use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5885827A (en) 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
AU4474497A (en) 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
GB9621113D0 (en) 1996-10-10 1996-11-27 Univ Southampton Transgenic fish
EP0963441A4 (en) 1996-12-02 2002-10-02 Univ Wake Forest THERAPY OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY INACTIVATION OF HIV CO-RECEPTORS
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
JP3692542B2 (ja) * 1997-01-21 2005-09-07 ザ ジェネラル ホスピタル コーポレーション Ｒｎａ−蛋白質の融合体を用いた蛋白質の選抜
WO1998039416A1 (en) † 1997-03-06 1998-09-11 Infigen, Inc. Method of cloning animals
ES2242997T3 (es) 1997-03-14 2005-11-16 Biogen Idec Inc. Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo.
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
EP1787999B1 (en) 1997-04-07 2010-08-04 Genentech, Inc. Anti-VEGF antibodies
JP4213224B2 (ja) † 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
WO1999015684A2 (en) 1997-09-23 1999-04-01 Oxford Biomedica (Uk) Limited Expression of genes in hematopoietic stem cells in hischaemic conditions
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ATE461282T1 (de) 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
ATE265835T1 (de) 1997-11-26 2004-05-15 Mitsubishi Precision Co Ltd Informationsleitungssystem
US6074385A (en) 1998-02-03 2000-06-13 Kiefer Corp. Hair follicle devitalization by induced heating of magnetically susceptible particles
EP1068524A4 (en) 1998-03-30 2005-01-26 Res Dev Foundation CORTICOTROPHIN RELEASE FACTOR RECEPTOR DEFICIENT MOUSE 1
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
CN1241574A (zh) * 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体
GB9823930D0 (en) † 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
EP1151002A4 (en) 1999-01-29 2002-05-02 Imclone Systems Inc KDR-SPECIFIC ANTIBODIES AND USES THEREOF
WO2000063403A2 (en) † 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
ATE421976T1 (de) 1999-05-18 2009-02-15 Dyax Corp Fab fragmentbibliotheken und verfahren für deren verwendung
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
MXPA01013458A (es) 1999-06-25 2002-07-30 Genentech Inc Anticuerpos humanizados anti-erbb2 y tratamiento con anticuerpos anti-erbb2.
AU7491800A (en) 1999-09-15 2001-04-17 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
JP2003513635A (ja) 1999-11-01 2003-04-15 カイロン コーポレイション 発現ベクター、トランスフェクション系、およびそれらの使用方法
GB9928787D0 (en) * 1999-12-03 2000-02-02 Medical Res Council Direct screening method
DE60033455T2 (de) 1999-12-27 2007-11-29 Crucell Holland B.V. Menschlischer monoklonaler Antikörper gegen Ep-CAM und dessen Verwendung in Krebstherapie
AU2001245358A1 (en) † 2000-02-29 2001-09-12 Auburn University Production of antibodies in transgenic plastids
AU5720601A (en) 2000-04-26 2001-11-07 Elusys Therapeutics Inc Bispecific molecules and uses thereof
ATE411387T1 (de) 2000-05-16 2008-10-15 Univ Jefferson Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren
ATE420958T1 (de) 2000-06-29 2009-01-15 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
CN1334343A (zh) * 2000-07-14 2002-02-06 中国医学科学院肿瘤医院肿瘤研究所 抑制肿瘤生长的新抗体、其衍生物及其应用
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
EP1188771A1 (en) 2000-09-15 2002-03-20 U-BISys B.V. Libraries of human heavy chain variable fragments in a functional format
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
FR2817875B1 (fr) 2000-12-07 2005-03-18 Technopharm Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
ATE501251T1 (de) 2001-01-25 2011-03-15 Evolva Ltd Zellbibliothek
CA2435972C (en) 2001-01-26 2011-09-13 University Of Lausanne Matrix attachment regions and methods for use thereof
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP1379125A4 (en) 2001-03-22 2004-12-08 Abbott Gmbh & Co Kg TRANSGENIC ANIMALS THAT EXPRESS SPECIFIC ANTIBODIES FOR INTERESTING GENES AND THEIR USE
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CA2450285C (en) * 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002345421B2 (en) 2001-06-15 2006-11-16 Crucell Holland B.V. Chimaeric phages
ATE477280T1 (de) 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
DK1404872T3 (da) 2001-07-04 2007-02-19 Chromagenics Bv Fremgangsmåde til selektion af en DNA-sekvens med transkriptionsmodulerende aktivitet med en vektor indeholdende et element med en gentranskriptionsundertrykkende aktivitet
NZ531291A (en) 2001-08-21 2006-02-24 Univ Jefferson Recombinant anti rabies antibodies MAb JB.1 and Mab 57 and compositions and methods for making and using the same
MXPA04001566A (es) 2001-08-27 2004-05-17 Genentech Inc Un sistema para expresion y ensamblado de anticuerpos.
JP2005535282A (ja) 2001-11-16 2005-11-24 アイデック ファーマシューティカルズ コーポレイション 抗体のポリシストロニック発現
AU2002363861A1 (en) 2001-11-30 2003-06-10 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an intigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
ATE394673T1 (de) 2001-11-30 2008-05-15 Ca Nat Research Council Selbstanordnende moleküle
US20050037427A1 (en) 2001-12-10 2005-02-17 Erwin Houtzager Structure for presenting desired peptide sequences
US20030215914A1 (en) 2001-12-10 2003-11-20 Erwin Houtzager Structure for presenting desired peptide sequences
US7244592B2 (en) * 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
GB2387030A (en) 2002-03-26 2003-10-01 Thales Plc Compensation of mutual coupling in array antenna systems
WO2003102157A2 (en) 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
ITGE20020049A1 (it) 2002-06-05 2003-12-05 Ali Spa Dispositivo a pistone per la erogazione di quantitativi dosati di sostanze pastose, quali i gelati, applicabile alle macchine per la loro fa
EP1513936A2 (en) 2002-06-14 2005-03-16 Chromagenics B.V. Use of repression blocking sequences in methods for enhancing gene expression
JP4647309B2 (ja) 2002-06-14 2011-03-09 クロマジェニックス ビー．ブイ． 複数のタンパク質の同時生産のための方法；そこで使用するためのベクター及び細胞
AU2002368062A1 (en) 2002-06-26 2004-01-19 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
AU2003245129B2 (en) 2002-07-10 2008-09-04 Agostino Di Trapani Building block
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
BRPI0406678A (pt) 2003-01-07 2005-12-20 Symphogen As Método para produzir proteìnas policlonais recombinantes
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
AU2004245429A1 (en) 2003-06-10 2004-12-16 Farallone Holding Bv Binding peptides: methods for their generation and use
WO2005012360A2 (en) 2003-07-22 2005-02-10 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
ES2378767T3 (es) 2003-12-23 2012-04-17 Crucell Holland B.V. Molécula de unión humana contra CD1a
JP5912211B2 (ja) * 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
CN102212132A (zh) 2004-05-27 2011-10-12 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
JP4487068B2 (ja) 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
NZ553409A (en) 2004-10-12 2010-04-30 Crucell Holland Bv Binding molecules for treatment and detection of acute myeloid leukaemia
NZ553701A (en) 2004-11-11 2009-12-24 Crucell Holland Bv Composition comprising SC03-014 and SC03-022 antibodies against SARS-CoV
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
WO2006117699A2 (en) 2005-04-29 2006-11-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
ATE507242T1 (de) 2005-05-12 2011-05-15 Crucell Holland Bv Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
WO2006136601A1 (en) 2005-06-23 2006-12-28 Crucell Holland B.V. Optimization of west nile virus antibodies
WO2007031550A2 (en) 2005-09-15 2007-03-22 Crucell Holland B.V. Method for preparing immunoglobulin libraries
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
CA2638774C (en) 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
RS52643B (en) 2006-06-02 2013-06-28 Regeneron Pharmaceuticals Inc. HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
AU2007255384B2 (en) 2006-06-06 2012-09-27 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
MX2009002174A (es) 2006-09-07 2009-03-12 Crucell Holland Bv Moleculas de union humanas capaces de neutralizar el virus de la influenza h5n1 y usos de las mismas.
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
ITMI20071522A1 (it) 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
MX2010002661A (es) 2007-09-14 2010-05-20 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
AU2009211148B2 (en) 2008-02-05 2014-08-28 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
EP3456193A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
WO2010084197A1 (en) 2009-01-26 2010-07-29 Genmab A/S Methods for producing mixtures of antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
PT2606064E (pt) 2010-08-16 2015-06-08 Novimmune Sa Processos para a geração de anticorpos poliespecíficos e polivalentes
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
MX343009B (es) 2011-02-25 2016-10-21 Regeneron Pharma Ratones de una desintegrina y metaloproteasa 6 (adam6).
AU2012235758B2 (en) 2011-03-25 2015-05-07 Ichnos Sciences SA Hetero-dimeric immunoglobulins
JP2013004215A (ja) 2011-06-14 2013-01-07 Hitachi Ltd リチウムイオン二次電池
JP2016184957A (ja) 2012-02-09 2016-10-20 シャープ株式会社 情報処理装置及び情報処理方法
EA202090591A3 (ru) 2012-04-20 2020-12-30 Мерюс Н.В. СПОСОБЫ И СРЕДСТВА ДЛЯ ПОЛУЧЕНИЯ Ig-ПОДОБНЫХ МОЛЕКУЛ
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t

Also Published As

Publication number Publication date
WO2004009618A3 (en) 2004-11-04
WO2004009618A2 (en) 2004-01-29
CA2965865A1 (en) 2004-01-29
JP2016220696A (ja) 2016-12-28
US20180094289A1 (en) 2018-04-05
US20130243773A1 (en) 2013-09-19
CA2872136A1 (en) 2004-01-29
US10934571B2 (en) 2021-03-02
PT2314629E (pt) 2014-01-22
CY1111886T1 (el) 2015-11-04
DK1523496T3 (da) 2011-10-17
EP1523496B1 (en) 2011-06-29
ES2442615T3 (es) 2014-02-12
CN105884893A (zh) 2016-08-24
DK2314629T4 (da) 2023-02-06
US20070077624A1 (en) 2007-04-05
CA2492377A1 (en) 2004-01-29
CN101537180A (zh) 2009-09-23
AU2003250074B2 (en) 2010-09-09
AU2003250074A1 (en) 2004-02-09
ES2368733T3 (es) 2011-11-21
EP2314629B1 (en) 2013-10-16
US7927834B2 (en) 2011-04-19
EP1523496A2 (en) 2005-04-20
US20070054362A1 (en) 2007-03-08
AU2010249150B2 (en) 2012-10-04
EP2314629A1 (en) 2011-04-27
CN101537180B (zh) 2016-02-10
US20090263864A1 (en) 2009-10-22
US7262028B2 (en) 2007-08-28
AU2010249150B9 (en) 2013-12-19
ES2442615T5 (es) 2023-03-16
DK2314629T3 (da) 2014-01-20
ATE514717T1 (de) 2011-07-15
US7932360B2 (en) 2011-04-26
JP2014204734A (ja) 2014-10-30
CN100480260C (zh) 2009-04-22
NZ537277A (en) 2008-04-30
CA2872136C (en) 2017-06-20
US9303081B2 (en) 2016-04-05
US20050170398A1 (en) 2005-08-04
JP6049239B2 (ja) 2016-12-21
CA2965865C (en) 2021-10-19
AU2010249150A1 (en) 2010-12-23
PT1523496E (pt) 2011-09-29
US20160319320A1 (en) 2016-11-03
US20180112247A1 (en) 2018-04-26
CN1668636A (zh) 2005-09-14
JP2011177193A (ja) 2011-09-15
CA2492377C (en) 2015-02-03
US7429486B2 (en) 2008-09-30
HK1070902A1 (en) 2005-06-30
US20110177073A1 (en) 2011-07-21
JP6166693B2 (ja) 2017-07-19
JP2006515503A (ja) 2006-06-01
JP4836451B2 (ja) 2011-12-14
EP2314629B2 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
HK1070902A1 (en) Recombinant production of mixtures of antibodies
GB0129105D0 (en) Expression control using variable intergenic sequences
EP1652925A4 (en) IGM PRODUCTION BY TRANSFORMED CELLS AND METHODS OF QUANTIFYING THE SAME
IL188094A0 (en) Il-1?? binding antibodies and fragments thereof
ATE443074T1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
WO2002016436A3 (en) ANTIBODIES TO HUMAN IL-1$g(b)
NZ594968A (en) Humanized c-kit antibody
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
HK1071898A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
HK1120556A1 (en) Neurotrophic factors
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
WO2003022868A3 (en) Metal binding proteins and associated methods
WO2005047325A3 (en) Monkey immunoglobulin sequences
WO2006013462A3 (en) Growth factors nsg28, nsg30, and nsg32
WO2003040301A3 (en) Cell cycle progression proteins
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
DE60326716D1 (de) Promoter Sequenzen aus Moos und dessen Verwendung
WO2002077023A3 (en) A new essential downstream component of the wingless signalling pathway
WO2004029577A3 (en) Hemipteran myosin light chain kinase